tbuckley/cabot-search huggingface dataset:
SAT0114 Trends in the incidence of solid tumors in patients with rheumatoid arthritis in spain. a national observational cohort study.
Authors: V. Villaverde, M. Fernandez-Prada, R. Mazzucchelli, E. Perez-Fernandez, C. Macía-Villa, M. Espinosa, J. Quiros, M. Peña, J. L. Morell, C. Morado-Quiñoa, C. Martínez-Prada, C. Barbadillo, H. Godoy, N. Crespí, O. Guzón-Illescas, M. Galindo, A. Herranz, A. García-Vadillo
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> During the last 20 years, the rheumatoid arthritis (RA) treatment has changed. Considering the increasing use of biological immunomodulators to treat this desease and the concern that immunomodulation may alter cancer risk, it's important to know the tumors incidence in RA. <h3>Objectives</h3> To analyze the incidence and trend of hospital admissions for solid tumors in patients with RA in Spain during the period between 1999 and 2015. <h3>Methods</h3> This is a retrospective population based study. We analized a national administrative database that includes a Minimum Basic Data Set (MBDS) of all hospital admissions of RA patients. Period: 1999 to 2015. We selected the MBDS for solid tumors. Cases were identified by the presence in primary and secondary diagnosis of ICD 9 codes. The population at risk was estimated through the population census of the National Institute of Statistics, with an estimated prevalence of RA of 0,5% (women: 0,8%, men:0,2%). Crude and adjusted rates of the solid tumors were calculated. The trend was analyzed by Generalized Linear Model (GLM). <h3>Results</h3> 338.343 RA hospital admissions were detected in the study period, being 18.401 (5,4%) due to solid tumors. The main clinical-demographic characteristics are shown in the next table. The solid tumor adjusted rate during the study period was 647,53/10<sup>5</sup> inhabitants/yr (366,97/10<sup>5</sup> in women and 1792,99/10<sup>5</sup> in men; relative risk men:women =4,8). This rate increased from 305,65/10<sup>5</sup> in 1999 to 993,19/10<sup>5</sup> inhabitants/yr in 2015 (from 814,06/10<sup>5</sup> in 1999 to 2535,5/10<sup>5</sup> in 2015 in men; from 181,68/10<sup>5</sup> in 1999 to 607,71/10<sup>5</sup> in 2015 in women). The annual age-adjusted rate increased significantly: 7,37% (6,52% in men and 8,02% in women; p≤0,001). figure1 <h3>Conclusions</h3> There was an increasing incidence of hospital admissions due to solid tumors in RA in Spain during the period 1999-2015. An annual rate increase of 7.37%, is estimated. <h3>Disclosure of Interest:</h3> None declared
FRI0441 Idiopathic inflammatory myopathies: clinical characteristics, survivial and poor prognostic factors of 110 patients from turkey
Authors: E. Oguz, M. Erdugan, B.A. Esen, A. Gul, L. Ocal, M. Inanc
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> In this study, we aimed to assess clinical features, poor prognostic factors and survival analysis of patients with Idiopathic inflammatory myopathy (IIM). <h3>Methods</h3> Records of 110 patients with IIM that had at least 6 months of follow-up, fulfilling Bohan and Peter's criteria were analysed for this study. Survival analysis was done by using Kaplan Meier method and multiple "Cox" regression analysis was applied to calculate the effect of multipl factors. <h3>Results</h3> Sixty-eight percent of 110 patients was female, the mean age of the patients was 46 years, and the average follow up time was 77.5 months. Diagnosis of these patients was dermatomyositis (DM) in 68%, polymyositis (PM) in 26%, autoimmune necrotizing autoimmune myopathy (NOM), inclusion body miyositis (IBM) 6%. The percentage of periungual erythema, arthritis, dysphagia, respiratory muscle involvement and interstitial lung disease(ILD) 56, 22, 24, 32, 11 and 30. Malignancy was identified in 26% of patients. The percentages of malignancies diagnosed at the time of diagnosis, before the diagnosis and during the follow-up were 3.6, 11.8 and 8.2. The most frequent malignancy was breast cancer. Others are carcinoma of gastrointestinal tract, lung, and genitourinary tract. ANA was present in 36% and 12% of patients was positive for anti-Jo-1 antibody. The average daily dose of prednisolone was 7.5 mg, the average usage time was 35.5 months. Causes of death were aspiration pneumonia-sepsis (50%) and malignancy (25%). Significant associations with mortality was found between systemic symptoms, periungual erytema, respiratory muscle involvement, dysphagia, presence of malignancy. Mortality was higher in ANA negative patients (p&lt;0.001), Five and 10 year survival in these patients were 83% and 75%. Five year survival rate in patients with respiratory muscle involvement was 38% and 68% in those with dysphagia. The presence of systemic symptoms, and malignancies were identified as risk factors for mortality in multivariable analysis. <h3>Conclusions</h3> ILD and malignancies are frequent in our IIM cohort. Malignancies are mostly detected at diagnosis. The mortality rate was high and the most common cause was infection. 10 year survival rate was 79%. Malignancy, respiratory muscle involvement, dysphagia, negative ANA have a detrimental effect survival in IIM patients. <h3>Disclosure of Interest</h3> None declared
Radium 223-Mediated Zonal Cytotoxicity of Prostate Cancer in Bone
Authors: Eleonora Dondossola, Stefano Casarin, Claudia Paindelli, Elena M De-Juan-Pardo, Dietmar W Hutmacher, Christopher J Logothetis, Peter Friedl
Journal: JNCI Journal of the National Cancer Institute (2019)

Bone-targeting radiotherapy with Radium-223 (Rad-223), a radioisotope emitting genotoxic alpha-radiation with limited tissue penetrance (∼100 µm), prolongs the survival of patients with metastatic prostate cancer (PCa). Confoundingly, the clinical response to Rad-223 is often followed by detrimental relapse and progression, and whether Rad-223 causes tumor-cell directed cytotoxicity in vivo remains unclear. We hypothesized that limited radiation penetrance in situ defines outcome.We tested Rad-223 overall response by PC3 and C4-2B human PCa cell lines in mouse bones (n = 5-18 tibiae per group). Rad-223 efficacy at subcellular resolution was determined by intravital microscopy analysis of dual-color fluorescent PC3 cells (n = 3-4 mice per group) in tissue-engineered bone constructs. In vivo data were fed into an in silico model to predict Rad-223 effectiveness in lesions of different sizes (1-27, 306 initial cells; n = 10-100 simulations) and the predictions validated in vivo by treating PCa tumors of varying sizes in bones (n = 10-14 tibiae per group). Statistical tests were performed by two-sided Student t test or by one-way ANOVA followed by Tukey's post-hoc test.Rad-223 (385 kBq/kg) delayed the growth (means [SD]; comparison with control-treated mice) of PC3 (6.7 × 105[4.2 × 105] vs 2.8 × 106 [2.2 × 106], P = .01) and C4-2B tumors in bone (7.7 × 105 [4.0 × 105] vs 3.5 × 106 [1.3 × 106], P < .001). Cancer cell lethality in response to Rad-223 (385 kBq/kg) was profound but zonally confined along the bone interface compared with the more distant tumor core, which remained unperturbed (day 4; 13.1 [2.3%] apoptotic cells, 0-100 µm distance from bone vs 3.6 [0.2%], >300 µm distance; P = .01).In silico simulations predicted greater efficacy of Rad-223 on single-cell lesions (eradication rate: 88.0%) and minimal effects on larger tumors (no eradication, 16.2% growth reduction in tumors of 27 306 cells), as further confirmed in vivo for PC3 and C4-2B tumors.Micro-tumors showed severe growth delay or eradication in response to Rad-223, whereas macro-tumors persisted and expanded. The relative inefficacy in controlling large tumors points to application of Rad-223 in secondary prevention of early bone-metastatic disease and regimens co-targeting the tumor core.
Dysphagia in the Elderly: What Does it Mean to the Endoscopist?
Authors: P Bannister, A J Stanners, R A Mountford
Journal: Journal of the Royal Society of Medicine (1990)

The role of fibreoptic endoscopy in the investigation of dysphagia in an elderly population was investigated. Three hundred and sixty-five subjects were studied. Two hundred and sixty subjects had abnormalities with extra oesophageal disease accounting for symptoms in a substantial minority. Endoscopy was safe, offered the advantage of immediate therapy and was well tolerated. Sub-group analysis showed it to be preferable to radiological investigation in diagnosing both benign and malignant mucosal lesions.
THU0580 The acr recommendations for jia in daily clinical practice: are they followed or would treat-to-target therapy lead to better results?
Authors: J.F. Swart, S. de Roock, P. van Dijkhuizen, N. Wulffraat
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> What factors drive the physician decision to escalate to anti-TNF therapy 3 and 6 months after start of methotrexate (MTX) in both persisting oligoarthritis (OJIA) and polyarticular course (PJIA) juvenile idiopathic arthritis. <h3>Objectives</h3> Are the escalation-decisions in accordance with the ACR JIA treatment recommendations (ACR-CPG)<sup>1</sup> and if not, what factors drive these decisions. How does it perform as a "prognostic" test to predict failure when not escalated. Could the clinical Juvenile Arthritis Disease Activity Score (cJADAS) be used instead. What is the value of the patient-VAS in the ACR-CPG, the physician decision and in the cJADAS. <h3>Methods</h3> Monocentric retrospective cohort study analysing all OJIA and PJIA patients starting MTX for the first time between 2011 and 2016. <h3>Results</h3> The ACR-CPG is mostly not followed and implementation would increase the anti-TNF-use from 12.0% to 65.1%. However, the physician decision not to escalate was now correct in 70%–75%, therefor implementation results in an overuse of anti-TNF. Some items of the ACR-CPG were non-discriminatory. The use of cJADAS in predicting failure if not escalated outperformed the ACR-CPG with a much higher sensitivity and specificity for the OJIA and PJIA group respectively. The omission of the patient-VAS-scores resulted in a substantial decrease of the identification of patients failing to respond without escalation. <h3>Conclusions</h3> The ACR-CPG not only is too complicated to be applicable in clinical practice, it also fails to identify those patients really in need of escalation to anti-TNF. The cJADAS can be used instead since this is user-friendly, does not require waiting for ESR results and performs better than the ACR-CPG. The patient-VAS is a critical item for the decision to escalate. <h3>Reference</h3> [1] Beukelman T, et al. 2011American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features. Arthritis Care Res (Hoboken)2011;63:465–82. <h3>Disclosure of Interest</h3> None declared
Abstract 18416: Discordance Between nonHDLc and Lipoprotein Particle Concentration (apoB and LDLp) in Relation to Future Coronary Events in Women
Authors: Patrick R Lawler, Akintunde O Akinkuolie, Paul M Ridker, Allan D Sniderman, Robert J Glynn, Julie Buring, Samia Mora
Journal: Circulation (2015)

Background: There remains equipoise as to which plasma lipid/lipoprotein marker most accurately reflects longitudinal risk of coronary heart disease (CHD) events. To compare differences in risk related to nonHDLc (atherogenic particle cholesterol) and LDL particle number (LDLp) or apoB (atherogenic particle number), we examined risk when these markers were discordant. Methods and Results: We divided 27,533 initially-healthy women in the Women’s Health Study (NCT00000479) into concordant/discordant groups based on median nonHDLc (154 mg/dL) and apoB (100 mg/dL) or 1 H NMR-measured LDLp (1,216 nmol/L). Discordance was defined as nonHDLc &lt; median and the alternative measure ≥ median, or vice versa. We compared risks between concordant and discordant groups (using the concordant group as reference) with Cox proportional hazard models adjusted incrementally for: age; and randomization arm, hormone use, postmenopausal status, smoking, and hypertension (“minimally adjusted”); and diabetes, BMI, hsCRP, HDLc, triglycerides, and family history of CHD (“fully adjusted”). Although all 3 biomarkers were strongly correlated - nonHDLc and apoB (Spearman r=0.86, P&lt;0.0001), nonHDLc and LDLp (r=0.77, P&lt;0.0001), and apoB and LDLp (r=0.85, P&lt;0.0001) - discordance between nonHDLc and apoB or LDLp occurred in 13.9% and 20.2% of women, respectively. A total of 1,246 CHD events occurred over median (max) 20.4 (21.7) years of follow-up (514,725 person-years). With nonHDLc &lt; median (Fig. a), CHD risk was underestimated among women with discordant high apoB or LDLp: fully adjusted HR (95% CI) high apoB = 1.33 (1.04, 1.71); high LDLp = 1.27 (1.01, 1.61). Alternately, with nonHDLc ≥ median (Fig. b), CHD risk was overestimated among women with discordant low apoB or LDLp: fully adjusted HR [95% CI] low apoB = 0.74 (0.57, 0.96); low LDLp = 0.93 (0.76, 1.14). Conclusions: For women with discordant levels of nonHDLc with apoB or LDLp, CHD risk may be underestimated or overestimated with nonHDLc.
NFkB reporter signaling distinguishes gemcitabine sensitive from resistant cell lines
Authors: Tameyoshi Yamamoto, Thiruvengadam Arumugam, Xue Pan, Craig Logsdon
Journal: Cancer Research (2007)

1190  Background and Aims: Pancreatic cancer is still one of the most dreadful cancers among malignancies. While some patients respond well to the standard chemotherapy, gemcitabine, most do not. Similarly some pancreatic cancer cells are relatively sensitive to gemcitabine while others are more resistant. It would be highly useful to be able to distinguish patients that respond from those that do not with greater accuracy and ease than is currently possible. In the present study, we sought to determine whether NFkB activity could predict sensitivity to gemcitabine or be used to distinguish sensitive from resistant cell lines. Methods: Pancreatic cancer cell growth inhibition with gemcitabine was evaluated by MTS assay. For analysis of NFκB activity, six pancreatic cancer cells (L3.6pl, BxPC3, CFPAC, Miapaca, MPanc96, and Panc1) and normal pancreatic duct epithelial cells (HPDE) were stably transfected using lentiviral vectors with both an NFκB reporter which utilizes NFκB response elements to drive firefly luciferase and with a control reporter that uses a CMV promoter to drive renilla luciferase. Cells were plated in 96 well plates and lysed after 24 and 48 hours with or without various concentration of gemcitabine. Luciferase activity was measured using the dual-luciferase reporter assay system and a luminometer. Results: Three of six cell lines (L3.6pl, BxPC3 and CFPAC) were relatively sensitive, whereas the other three (Miapaca, MPanc96 and Panc1) cells were very resistant to gemcitabine. All six pancreatic cancer cells displayed high basal NFκB activity. No correlation was observed between basal NFκB activity and sensitivity to gemcitabine. Gemcitabine treatment increased NFκB activity in both sensitive (L3.6pl 3-fold increase) and resistant (Panc1 2-fold increase) cells at 24 hours. However, after 48 hours the NFκB reporter activity was greatly reduced in sensitive cells as a result of cell death. In contrast, NFκB reporter signaling remained elevated in resistant cells. Conclusion: This study found that basal NFκB activity does not correlate with the sensitivity to gemcitabine. However, the alteration of NFκB reporter signaling during the treatment with gemcitabine can distinguish resistant from sensitive cells.
Diversity and Richness Analysis of the Oral and Gastrointestinal Microbiome during Autologous Transplantation for Multiple Myeloma: Results of a Prospective Pilot Study and Correlation with Transplant Outcomes
Authors: Najla H El Jurdi, Ali Filali, Iman Salem, Mauricio Retuerto, Nina Dambrosio, Hillard M Lazarus, Paolo F Caimi, Richard Creger, Brenda Cooper, Ben Tomlinson, Leland Metheny, Ehsan Malek, Folashade Otegbeye, Rafick-Pierre Sekaly, Mahmoud Ghannoum, Marcos de Lima
Journal: Blood (2018)
THU0511 Effects of add-on transcranial direct current stimulation on pain in korean patients with fibromyalgia
Authors: J.-H. Kang, K.-E. Lee, D.-J. Park, S.-S. Lee
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Objectives</h3> Despite promising preliminary results of transcranial direct current stimulation (tDCS) treatment in patients with fibromyalgia (FM), several issues need to be addressed, including its limited efficacy, low response rate, and poor tolerability. We investigated the efficacy and safety of tDCS as an add-on treatment for chronic widespread pain in Korean patients with FM. <h3>Methods</h3> This study enrolled 38 patients, who were refractory to pain medications, seen at Chonnam National University Hospital from May 2016 to December 2016. A conventional tDCS device was used to supply 2 mA of current for 20 min on 5 consecutive days. The anode was placed over the primary motor cortex (M1) and the cathode was located contralateral supraorbital area. The primary end point was a change in visual analogue scale (VAS) pain score at the end of treatment and secondary end points included changes in Fibromyalgia Impact Questionnaire (FIQ), Brief Pain Inventory (BPI), Brief Fatigue Inventory (BFI), Beck Depression Inventory (BDI), State-Trait Anxiety Inventory (STAI), and Medical Outcomes Study Sleep Scale scores. <h3>Results</h3> After tDCS, 38 patients showed clinical improvements in the VAS pain score on days 6, 13 and 36 compared with day 0 (p=&lt;0.001). However, improvement of FIQ scores was only seen at day 36. The BPI and BDI were significantly decreased on days 6 and 13, while BFI and STAI-I were significantly improved only at day 6. The most of improved indices were not maintained until day 36. There were no significant improvements in Sleep Scale scores after tDCS at days 6, 13, and 36. No serious adverse event was observed. <h3>Conclusions</h3> Our results suggest that tDCS has the potential to produce significant pain relief in FM patients, and may constitute an effective add-on treatment for these patients. <h3>Disclosure of Interest</h3> None declared
AB1283 The prevalence and comorbidities associated with psoriatic arthritis in patients with psoriasis: an observational cohort study
Authors: A.M. Abdalla, M.H. Abd El-Halim
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The prevalence and comorbidities of psoriatic arthritis (PsA) varies in different parts of the world and there is little clinical and epidemiological data from the Egyptian <h3>Objectives:</h3> To investigate the prevaalence of psoriatic arthritis (PsA) in patients with psoriasis (PsO), and to identify comorbidities associated with it. <h3>Methods:</h3> The study was designed as a observational cohort study involving patients with psoriasis. Information was collected about lifestyle, habits, comorbidities, and psoriasis activity. Patients were classified as having PsA if they fulfilled the criteria of the Classification of Psoriatic Arthritis Study group (CASPAR). <h3>Results:</h3> The data was obtained from the 371 psoriasis patients. The mean age was 40.0±16.6 years, 42% were women, and 58% were men. A diagnosis of PsA was found in 104 patients (28%), of whom 34.6% had peripheral involvement, 15.4% had isolated axial involvement, and 50% had both peripheral and axial involvement. The PsA onset was preceding psoriasis in 48%, together with psoriasis in 40% and following psoriasis in 12%. Family history of PsO and PsA was positive in 21.6% and 8.4% respectively. PASI score of our patients ranged from 1–30 with a mean of 8.77±6.33, which were relatively higher in PsA patients. Comorbidities in form of diabetes mellitus, hypertension, liver disease, HIV and dyslipidemia were found in 14.6%, 10.5%, 10.2%, 0.3% and 0.5% respectively. Smoking was found in only10 patients (2.7%). <h3>Conclusions:</h3> The prevalence of PsA in Egyptian patients with psoriasis appears to be within the range reported in other studies. Whereas, most of PsA onset was found to precede the psoriasis. <h3>Disclosure of Interest</h3> None declared
SAT0282 Occurrence of anterior uveitis in patients with spondyloarthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: a restrospective monocentric study comparing the soluble receptor to the monoclonal antibodies
Authors: G. Khoury, B. Combe, J. Morel, C. Lukas
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> The efficacy of tumour necrosis factor inhibitors against anterior uveitis has been shown, but discrepancies remain as to the difference in efficacy between soluble receptor and monoclonal antibodies. <h3>Objectives</h3> The objective of this study was to compare the occurrence of anterior uveitis with soluble receptor and monoclonal antibodies in patients with spondyloarthritis (SPA) and psoriatic arthritis (PA). <h3>Methods</h3> This was an observational, retrospective, monocentric study. Patients attending the rheumatology department of the Montpellier University Hospital for a SPA or a PA and who were prescribed anti-TNF agents between 2000 and 2014 were included in our cohort. Data on the diagnosis of rheumatism, the history of the disease and the extra-articular symptoms were collected from medical records. The risk of uveitis has been interpreted qualitatively (number of subjects with at least one flare of uveitis) and quantitatively (number of uveitis flares for each patient). Logistic regression models were used for qualitative analyses and Poisson models for quantitative analyses. <h3>Results</h3> 429 patients were included (302 with SPA and 127 with PA, 203 were treated with a monoclonal antibody as first TNF alpha inhibitor and 226 with the soluble receptor). No difference between monoclonal antibodies and soluble receptor was found in the risk of uveitis occurring during the first year of treatment (OR=0.94 [0.35; 2.54], p=0.90 in qualitative analysis and RR=0.62 [0.26; 1.46]; p=0.27 in quantitative analysis). The risk of uveitis was higher with the soluble receptor for the first-line TNF inhibitors, as well as for all therapeutic lines, but this difference was not statistically significant (p=0.09 and 0.08 respectively in quantitative analysis and 0.68 and 0.53 in quantitative analysis). <h3>Conclusions</h3> In view of our observations, the risk of uveitis does not appear to be significantly higher with the soluble receptor than with the monoclonal antibodies in SPA and PA, to recommend systematically the eviction of etanercept in subjects with a moderate risk of developing anterior uveitis. <h3>Disclosure of Interest</h3> None declared